CIRCULATE-Japan GALAXY: ctDNA-Based MRD Detection in Colorectal Cancer and Implications for Survival, Treatment, and Risk Stratification
Mike J. Pishvaian, MD, PhD; Stacey Cohen, MD; and Mark Lewis, MD, FASCO, discuss how recent advancements in circulating tumor DNA (ctDNA) and minimal residual disease (MRD) testing are revolutionizing colorectal cancer management across the care continuum, from early detection to treatment selection and monitoring, with key insights from major clinical trials like DYNAMIC and GALAXY informing more personalized and effective treatment strategies.
EP. 1: Colorectal Cancer: Rising Prevalence and the Promise of ctDNA
October 16th 2024Panelists discuss how colorectal cancer rates are increasing, particularly among younger adults, while highlighting the potential of circulating tumor DNA (ctDNA) technology to improve early detection and treatment monitoring.
EP. 2: ctDNA in CRC Management: Evolving Approaches for Personalized Care
October 16th 2024Panelists discuss how circulating tumor DNA (ctDNA) is revolutionizing colorectal cancer (CRC) management by enabling more personalized and precise approaches to diagnosis, treatment selection, and monitoring of disease progression.
EP. 3: MRD Detection in CRC: Guiding Postsurgical Treatment Decisions and Monitoring
October 22nd 2024Panelists discuss how minimal residual disease (MRD) detection in colorectal cancer (CRC) is improving postsurgical treatment decision-making and enabling more effective monitoring of patient outcomes.
EP. 4: MRD Testing in CRC: Optimizing Chemo-Sparing Strategies and Residual Disease Control
October 22nd 2024Panelists discuss how minimal residual disease (MRD) testing in colorectal cancer (CRC) is facilitating the development of chemo-sparing strategies while maintaining effective control of residual disease.
EP. 5: DYNAMIC: ctDNA-Guided Therapy on Adjuvant Chemotherapy Decisions in Stage II Colon Cancer
October 29th 2024Panelists discuss how the DYNAMIC trial data demonstrate the potential of circulating tumor DNA (ctDNA)–guided therapy to inform and optimize adjuvant chemotherapy decisions in patients with stage II colon cancer.
EP. 6: ctDNA Insights From INTERCEPT, BESPOKE, COSMOS-CRC-01, and GALAXY Studies
October 29th 2024Panelists discuss how insights from the INTERCEPT, BESPOKE, COSMOS-CRC-01, and GALAXY studies are advancing our understanding of circulating tumor DNA’s (ctDNA) utility in colorectal cancer management, from early detection to treatment monitoring.
EP. 7: GALAXY Study: ctDNA-Based MRD Monitoring in Resected CRC
November 5th 2024Panelists discuss how the GALAXY study data demonstrate the effectiveness of circulating tumor DNA (ctDNA)–based minimal residual disease (MRD) monitoring in patients with resected colorectal cancer (CRC), potentially improving postsurgical care and outcomes.
EP. 8: GALAXY Study Results: ctDNA Status Predicts Outcomes and Treatment Benefit in CRC
November 5th 2024Panelists discuss how results from the GALAXY study reveal that circulating tumor DNA (ctDNA) status is a powerful predictor of outcomes and treatment benefit in patients with colorectal cancer (CRC), potentially revolutionizing personalized treatment approaches.
EP. 9: Treatment Strategies in ctDNA-Positive CRC
November 12th 2024Panelists discuss how treatment strategies for circulating tumor DNA (ctDNA)–positive colorectal cancer (CRC) are evolving, with a focus on tailoring interventions based on molecular findings to improve patient outcomes and minimize unnecessary therapies.
EP. 10: GALAXY 24-Month Data from ESMO 2024: MRD Status and ctDNA Clearance Key in CRC
November 12th 2024Panelists discuss how the 24-month data from the GALAXY study presented at the European Society for Medical Oncology (ESMO) 2024 meeting underscore the importance of minimal residual disease (MRD) status and circulating tumor DNA (ctDNA) clearance as key prognostic and predictive factors in colorectal cancer (CRC) management.
EP. 11: CLM in GALAXY: MRD Predicts Adjuvant Therapy Benefit and Prognosis
November 12th 2024Panelists discuss how minimal residual disease (MRD) detection in patients with colorectal liver metastases (CLM) in the GALAXY study predicts both the benefit of adjuvant therapy and overall prognosis, potentially guiding more personalized treatment decisions.
